Lupin Pharmaceuticals Initiates Class II Recall of Cefdinir Oral Suspension Due to Foreign Material
Lupin Pharmaceuticals Inc. has initiated a Class II recall for 17,070 bottles of Cefdinir for Oral Suspension USP 250 mg/5 mL due to foreign material contamination. This voluntary, nationwide recall impacts a critical generic antibiotic, requiring immediate action from procurement and supply chain leaders to assess inventory and mitigate potential disruptions.
FDA Class II Recall for Lupin's Cefdinir Oral Suspension: Foreign Material Contamination
Lupin Pharmaceuticals Inc., based in Baltimore, Maryland, has initiated a voluntary Class II recall, designated D-0496-2024, for its Cefdinir for Oral Suspension USP 250 mg/5 mL. This recall, initiated on April 24, 2024, addresses a critical quality issue: the presence of foreign material reported in a reconstituted bottle of the product. Specifically, 17,070 bottles from Lot # F305442, with an expiration date of August 30, 2025, are affected. The product is distributed nationwide across the USA. A Class II classification signifies that the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. For procurement directors and supply chain VPs, this means immediate action is required to identify and quarantine any affected inventory. Failure to do so could expose your organization to significant regulatory risk, potential patient safety issues, and reputational damage. Regulatory affairs heads must ensure internal procedures align with FDA recall guidelines, including communication protocols for healthcare providers and patients.
Global Manufacturing Origin and Quality Control Implications for Lupin
The recalled Cefdinir for Oral Suspension, while distributed by Lupin Pharmaceuticals Inc. from its Baltimore, Maryland location, is manufactured by Lupin Limited in Mandideep 462 046, India. This highlights the globalized nature of pharmaceutical supply chains and the inherent complexities in maintaining consistent quality control across international manufacturing sites. Cefdinir, a cephalosporin antibacterial, is a widely used generic antibiotic, making its uninterrupted supply crucial for healthcare systems. The reported foreign material complaint underscores potential vulnerabilities in manufacturing processes, such as inadequate environmental controls or material handling practices at the Mandideep facility. For supply chain VPs, this event necessitates a rigorous review of your third-party manufacturing audit programs, particularly for critical generic APIs and finished products sourced from regions like India. Business development executives should assess the competitive landscape for Cefdinir, as quality incidents can shift market share and create opportunities for alternative suppliers demonstrating robust quality systems.
Commercial Impact: Nationwide Distribution and Market Disruption for Cefdinir
The recall of 17,070 bottles of Cefdinir for Oral Suspension, distributed USA nationwide, carries significant commercial implications. Cefdinir is a key generic antibiotic, and a disruption in its supply, even for a single lot, can impact patient access and create procurement challenges. The product is associated with FDA application number ANDA065259 and NDC 68180-723-04, indicating its established presence in the U.S. market. Procurement directors must immediately verify if their organizations have received or dispensed Lot # F305442. The financial impact extends beyond the cost of returned product, encompassing potential stockouts, administrative burdens of managing the recall, and the need to expedite sourcing from alternative suppliers. Business development executives should monitor market dynamics closely, as this recall could lead to increased demand for other Cefdinir manufacturers or alternative antibiotics, presenting strategic opportunities for competitors with stable supply chains and strong quality records.
Regulatory Oversight and Broader Industry Compliance Trends
This Class II recall by Lupin Pharmaceuticals Inc. reflects the FDA's ongoing vigilance in ensuring drug product quality and patient safety across the pharmaceutical industry. While the provided intelligence does not indicate a specific prior regulatory history for Lupin in our knowledge graph, this event aligns with a broader trend of increased scrutiny on manufacturing quality. Recent parallel events, such as Essential Wellness Pharma's Class II recall for Progesterone Injection due to sterility failures and the FDA hearing concerning Amgen's Tavneos market future, underscore the agency's consistent enforcement posture. For regulatory affairs heads, this emphasizes the critical importance of maintaining robust Quality Management Systems (QMS) and ensuring continuous compliance with Current Good Manufacturing Practices (cGMP). Proactive internal audits and supplier qualification programs are essential to identify and rectify potential issues before they escalate to FDA actions, which can result in significant operational and financial repercussions.
Recall Resolution: Termination Status and Corrective Action Expectations
The FDA officially classified this recall as 'Terminated' on April 29, 2025, following its initiation on April 24, 2024. A 'Terminated' status indicates that the FDA has reviewed the firm's actions and is satisfied that the recall has been effectively completed. However, this does not absolve Lupin of the responsibility to conduct a thorough root cause investigation into the foreign material contamination and implement comprehensive corrective and preventive actions (CAPA). For regulatory affairs and quality assurance teams, understanding the full scope of Lupin's CAPA plan is crucial. This includes assessing whether the identified root cause was specific to Lot # F305442 or indicative of systemic issues at the Mandideep manufacturing facility. Procurement directors should seek assurances from Lupin regarding the efficacy of these corrective actions to prevent recurrence and ensure the long-term quality and reliability of future Cefdinir supplies. Ongoing monitoring of Lupin's manufacturing sites will be vital for maintaining supply chain confidence.
Strategic Sourcing and Risk Mitigation for Essential Generic Medicines
The recall of Cefdinir, a critical cephalosporin antibiotic, highlights the imperative for robust strategic sourcing and risk mitigation strategies within the global chemical and life sciences industry. Supply chain VPs must prioritize diversifying their supplier base for essential generic medicines, particularly those with complex international manufacturing origins. Relying on a single source, or a limited number of sources, for high-volume or medically necessary products like Cefdinir introduces significant vulnerability. While the provided knowledge graph does not list alternative suppliers for Cefdinir, procurement teams should proactively identify and qualify secondary and tertiary manufacturers to ensure business continuity. This involves comprehensive due diligence, including on-site audits, quality system assessments, and rigorous product testing. Business development executives can leverage this event to identify market gaps and position their organizations as reliable, quality-focused suppliers of generic antibiotics, emphasizing supply chain resilience and robust quality control as key differentiators in a competitive market.